NasdaqGS:REPLBiotechs
How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For New Melanoma Therapy
Earlier this month, Replimune Group announced that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma that has progressed after anti-PD-1 antibody-based therapy.
This decision brings the first approved oncolytic HSV-1 viral therapy for this difficult-to-treat melanoma setting into clinical practice, anchored on objective response rate and duration of response from the...